Cover Image
Market Research Report

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

Published by GlobalData Product code 316761
Published Content info 165 Pages
Immediate Delivery Available
Price
Back to Top
PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023
Published: September 30, 2014 Content info: 165 Pages
Description

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

The high incidence of HER2-positive breast cancer in the US, almost equaling that of the entire 5EU, and the high treatment rates in the neoadjuvant and adjuvant settings using HER2-targeted therapies in all stages, have helped drive the sales of HER2-positive therapeutics in the US. HER2-targeting therapies are priced at a premium in the US, owing to the country's private health insurance system, which can most easily afford to reimburse the latest expensive drugs.

Scope

  • An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the US HER2-Positive Breast Cancer market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for HER2-Positive Breast Cancer.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the HER2-Positive Breast Cancer sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the US HER2-Positive Breast Cancer market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the US HER2-Positive Breast Cancer market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the US HER2-Positive Breast Cancer market landscape Identify, understand and capitalize.
Table of Contents
Product Code: GDHC253CFR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Basic Breast Anatomy
  • 3.3. Breast Cancer Staging
  • 3.4. Prognosis
  • 3.5. Quality of Life
  • 3.6. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
    • 4.1.2. Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
    • 4.1.3. Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)
  • 4.2. US
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - HER2-Targeted Therapies
    • 5.2.1. Herceptin (trastuzumab)
    • 5.2.2. Tykerb (lapatinib)
    • 5.2.3. Perjeta (pertuzumab)
    • 5.2.4. Kadcyla (ado-trastuzumab emtansine, T-DM1)
  • 5.3. Product Profiles - General Targeted Therapies
    • 5.3.1. Afinitor (everolimus)
    • 5.3.2. Xeloda (capecitabine)
    • 5.3.3. Avastin (bevacizumab)
    • 5.3.4. Halaven (eribulin mesylate)
    • 5.3.5. Abraxane (nab-paclitaxel)
    • 5.3.6. Ixempra (ixabepilone)
  • 5.4. Hormonal Agents
    • 5.4.1. Tamoxifen
    • 5.4.2. Faslodex (fulvestrant)
    • 5.4.3. Aromatase Inhibitors

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Brain Metastases
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Resistance to HER2-Targeting Therapies
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Gilotrif (afatinib)
    • 7.2.2. Neratinib
  • 7.3. Promising Drugs in Early-Stage Development
    • 7.3.1. Palbociclib
    • 7.3.2. NeuVax (nelipepimut-S)
    • 7.3.3. Patritumab
    • 7.3.4. Ganetespib
    • 7.3.5. ARRY-380 (ONT-380)
    • 7.3.6. NVP-BYL719
  • 7.4. Biosimilars

8. Market Outlook

  • 8.1. United States
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. United States - Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed HER2-Positive Breast Cancer Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: AJCC Stage Definitions for Breast Cancer
  • Table 2: Prognosis for Breast Cancer in the US
  • Table 3: Treatment Guidelines for HER2-Positive Breast Cancer
  • Table 4: Product Profile - Herceptin
  • Table 5: Clinical Studies for Herceptin in the Adjuvant Setting
  • Table 6: Herceptin SWOT Analysis, 2013
  • Table 7: Product Profile - Tykerb
  • Table 8: Tykerb SWOT Analysis, 2013
  • Table 9: Product Profile - Perjeta
  • Table 10: Perjeta SWOT Analysis, 2013
  • Table 11: Product Profile - Kadcyla
  • Table 12: Kadcyla SWOT Analysis, 2013
  • Table 13: Product Profile - Afinitor
  • Table 14: Afinitor SWOT Analysis, 2013
  • Table 15: Product Profile - Xeloda
  • Table 16: Xeloda SWOT Analysis, 2013
  • Table 17: Product Profile - Avastin
  • Table 18: Summary of Avastin Phase III Clinical Trials in Metastatic Breast Cancer
  • Table 19: Avastin SWOT Analysis, 2013
  • Table 20: Product Profile - Halaven
  • Table 21: Halaven SWOT Analysis, 2013
  • Table 22: Product Profile - Abraxane
  • Table 23: Abraxane SWOT Analysis, 2013
  • Table 24: Product Profile - Ixempra
  • Table 25: Ixempra SWOT Analysis, 2013
  • Table 26: Summary of Minor Therapeutic Classes Used to Treat HER-2 positive breast cancer, 2013
  • Table 27: Unmet Need and Opportunity in HER2-Positive Breast Cancer
  • Table 28: Product Profile - Gilotrif
  • Table 29: Gilotrif SWOT Analysis, 2014
  • Table 30: Product Profile - Neratinib
  • Table 31: Neratinib SWOT Analysis, 2013
  • Table 32: Comparison of Therapeutic Classes in Development for HER2-Positive/HER2-Negative Breast Cancer, 2014
  • Table 33: HER2-Positive Breast Cancer - Early-Phase Pipeline, 2014
  • Table 34: Product Profile - Palbociclib
  • Table 35: Palbociclib SWOT Analysis, 2014
  • Table 36: Product Profile - NeuVax
  • Table 37: NeuVax SWOT Analysis, 2014
  • Table 38: Product Profile - Patritumab
  • Table 39: Patritumab SWOT Analysis, 2014
  • Table 40: Product Profile - Ganetespib
  • Table 41: Ganetespib SWOT Analysis, 2014
  • Table 42: Product Profile - ARRY-380
  • Table 43: ARRY-380 SWOT Analysis, 2014
  • Table 44: Product Profile - NVP-BYL719
  • Table 45: NVP-BYL719 SWOT Analysis, 2014
  • Table 46: Trastuzumab Biosimilars, 2014
  • Table 47: Sales Forecast ($m) for HER2-Positive Breast Cancer in the US, 2013-2023
  • Table 48: Key Events Impacting Sales for HER2-Positive Breast Cancer in the US, 2013-2023
  • Table 49: Global HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 50: US HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
  • Table 51: HER2-Positive Breast Cancer Incidence, 2013-2023
  • Table 52: HER2-Positive Breast Cancer Drugs, Key Launch Dates
  • Table 53: HER2-Positive Breast Cancer Drugs, Key Patent Expiries
  • Table 54: Average Body Weight and Surface Area in the US
  • Table 55: Average Annual Cost of Therapy ($) - Herceptin, Adjuvant
  • Table 56: Average Annual Cost of Therapy ($) - Perjeta, First Line
  • Table 57: Average Annual Cost of Therapy ($) - Tykerb, First Line
  • Table 58: Average Annual Cost of Therapy ($) - Kadcyla, Second Line
  • Table 59: Average Annual Cost of Therapy ($)- Halaven, Fourth Line
  • Table 60: Average Annual Cost of Therapy ($) - Abraxane, Fourth Line
  • Table 61: Average Annual Cost of therapy ($) - Ixempra, Fourth Line
  • Table 62: Average Annual Cost of Therapy ($) - Neratinib, Third Line
  • Table 63: Physicians Surveyed by Country

List of Figures

  • Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
  • Figure 2: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb
  • Figure 3: Active Late-Stage Clinical Trials for Perjeta
  • Figure 4: Active Phase III Clinical Trials for Kadcyla
  • Figure 5: Active Phase III Clinical Trials for Afinitor
  • Figure 6: Clinical Trials for Halaven
  • Figure 7: HER2-Positive Breast Cancer - Phase II-III Pipeline, 2013
  • Figure 8: Gilotrif's Clinical Development in Breast Cancer
  • Figure 9: Clinical and Commercial Positioning of Gilotrif
  • Figure 10: Neratinib's Clinical Development
  • Figure 11: Clinical and Commercial Positioning of neratinib.
  • Figure 12: Sales for HER2-Positive Breast Cancer in the US by Drug Class, 2013-2023
Back to Top